Aliko Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), a life sciences group focused on integrated oncology diagnostics, has launched its business development collaboration with Partner International Inc. The initiative aims to accelerate the company’s commercial development, particularly in the United States.

The collaboration was launched at ADLM 2026 in Anaheim, California, one of the leading global events for laboratory medicine and diagnostics. The event brought together more than 700 exhibitors covering a wide range of diagnostic and laboratory technologies.

Under the agreement, Partner International will support Aliko Scientific in developing the US market by identifying and approaching potential customers, distributors, commercial partners and strategic opportunities across the life sciences and diagnostics sectors.

The partnership will also support Aliko Scientific’s wider international expansion. Activities will include identifying distributors in priority markets, developing partnerships with diagnostics, pathology and laboratory companies, exploring technology integration opportunities, and expanding relationships with laboratory networks and healthcare organisations.

Partner International will also help move potential opportunities from initial discussions through to negotiations and agreements.

The companies reported strong interest in Aliko Scientific’s technologies during their first joint initiative at ADLM 2026. Several discussions are expected to progress into further business development activities in the coming months, including potential strategic partnerships with major organisations in the diagnostics and life sciences sectors.

The US remains a key market for Aliko Scientific because of its scale, healthcare volumes and commercial potential. The company is focusing its international growth strategy on markets with opportunities for cytology, fluorescence in situ hybridisation (FISH), automated imaging and precision oncology diagnostics.

Aliko Scientific is also developing a global oncology diagnostics platform through its businesses Ikonisys and Hospitex International. Ikonisys provides automated molecular cancer diagnostics that combine high-precision microscopy, FISH analysis and artificial intelligence. Hospitex International contributes expertise in precision cytology and standardised sample preparation.

Together, these capabilities provide an integrated portfolio covering several stages of the diagnostic workflow.

The collaboration with Partner International is expected to help Aliko Scientific expand its international market presence, establish new distribution channels and develop strategic relationships to increase the global adoption of its oncology diagnostic technologies.

 

Source: alikoscientific.com

Report Abuse